The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Litigation against Lansen's sub in Ningbo, the PRC

6 Jul 2015 10:25

RNS Number : 2512S
Cathay International Holdings Ld
06 July 2015
 

 

Cathay International Holdings Limited

("Cathay", the "Company" or the "Group")

 

Litigation against Lansen's subsidiary in Ningbo, the PRC

 

Hong Kong, 6 July 2015 - Cathay International Holdings Limited (LSE: CTI.L), a leading operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"), today announces that its subsidiary, Lansen Pharmaceutical Holdings Ltd ("Lansen") (HKEX: 503), in which the Company has a 50.56% holding, has made a regulatory announcement in accordance with the requirements of its Hong Kong listing.

 

The board of directors of Lansen has informed its shareholders and potential investors that it has recently come to its attention that Neptunus Medicine Company Limited (the "Claimant"), a subsidiary of Shenzhen Neptunus Biological Engineering Company Limited ("Shenzhen Neptunus") has initiated legal proceedings as plaintiff (the "Litigation") against Ningbo Liwah Pharmaceutical Company Limited ("Ningbo Liwah"), a wholly owned subsidiary of Lansen in Ningbo, the PRC. According to an announcement published by Shenzhen Neptunus, the Claimant had submitted a writ of summons at Shenzhen Intermediate People's Court and the court had issued a notice of case acceptance. As at the date of this announcement, Ningbo Liwah has not received any court documents in relation to the Litigation. In the Litigation, the Claimant alleged that it had suffered several losses due to the use of ginkgo extract supplied by Ningbo Liwah in Claimant's products. The Claimant is therefore seeking damages of approximately RMB70 million (approximately USD11.2 million at the current exchange rate) from Ningbo Liwah, as well as relevant legal fees.

 

Lansen has sought a preliminary opinion on the Litigation from its legal counsel in the PRC, who, based on the information available as of the date of this announcement, is of the opinion that the amount claimed by the Claimant is highly disputable. Lansen will, in accordance with the applicable laws, make every effort to protect its interests and its shareholders' interests, actively respond to the case and defend its position vigorously. Lansen will closely monitor the development of this matter and make further announcements if and when there are any significant developments in relation to it.

 

Cathay will inform shareholders of any material developments or notify the market when Lansen makes an announcement relevant to the above proceedings.

 

-ENDS-

 

For further enquiries, please contact:

 

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

Tel: +852 2828 9289

 

N+1 Singer

+44 (0) 20 7496 3000

Aubrey Powell - Corporate Finance

Brough Ransom - Sales

 

Consilium Strategic Communications

Mary-Jane Elliott/ Matthew Neal / Lindsey Neville

Tel: +44 (0) 20 3709 5702

 

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China ("PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen Group, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

 

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk

 

About Lansen

Lansen, whose shares are listed on the mainboard of the Hong Kong Stock Exchange, is a 50.56% owned subsidiary of Cathay. Lansen is engaged in the manufacture, distribution and development of specialty prescription drugs for treatment of autoimmune disorder in rheumatology and dermatology. Lansen is in the leading market position in disease modifying anti-rheumatic drugs ("DMARDs") for treatment of rheumatoid arthritis ("RA") in the PRC. Lansen has established an extensive distribution network, covering more than 1,000 hospitals in four municipalities, 25 provinces and cities in the PRC. For more information please visit the Lansen's website: http://www.lansen.com.cn/En/index.asp

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMMGGNLVRGKZG
Date   Source Headline
1st Dec 20205:39 pmRNSCompulsory Acquisition Notice
11th Nov 20209:46 amRNSResults of the Tender Offer
3rd Nov 202010:53 amRNSResult of SGM and Notification of change to Shares
3rd Nov 202010:08 amRNSLansen's seventh share reduction plan of Starry
2nd Nov 202010:11 amRNSDisposal of Starry Shares
29th Oct 202010:43 amRNSTotal Voting Rights
16th Oct 20206:16 pmRNSTender Offer and Notice of SGM
29th Sep 20201:14 pmRNSRequisition Notice
22nd Sep 202010:41 amRNSResults of Annual General Meeting
28th Aug 202012:10 pmRNSInterim Results
28th Aug 202011:57 amRNSNotice of AGM
27th Aug 20202:33 pmRNSLansen's Interim Results
21st Aug 202011:06 amRNSSecond Price Monitoring Extn
21st Aug 202011:00 amRNSPrice Monitoring Extension
14th Aug 20207:00 amRNSNotice of Interim Results 2020
3rd Aug 202011:21 amRNSBLOCK LISTING SIX MONTHLY RETURN
23rd Jul 20209:50 amRNSDisposal of Starry Shares
22nd Jul 202011:46 amRNSDisposal of Starry Shares
17th Jul 202012:12 pmRNSDisposal of Starry Shares
14th Jul 202010:09 amRNSTRANSFER OF LISTING
13th Jul 202011:17 amRNSPoll results of Lansen’s EGM
24th Jun 202010:46 amRNSDespatch of Circular by Lansen
15th Jun 202010:32 amRNSResult of General Meeting (“GM”)
5th Jun 20209:52 amRNSLansen update re Proposed Disposal
29th May 20202:18 pmRNSTotal Voting Rights
28th May 20202:49 pmRNSProposed transfer of listing and Notice of GM
21st May 20202:44 pmRNSTR-1: Notification of major holdings
20th May 20205:20 pmRNSTR-1: Notification of major holdings
18th May 20201:34 pmRNSDirector/PDMR Shareholding
24th Apr 20201:02 pmRNSPublication of Prospectus
21st Apr 20209:07 amRNSPublication and posting of Annual Report
9th Apr 202010:51 amRNSLansen's sixth share reduction plan of Starry
1st Apr 202010:39 amRNSAnnual Results for the year ended 31 December 2019
31st Mar 20202:37 pmRNSLansen reports annual results year ended 31 Dec 19
18th Mar 20207:00 amRNSNotice of Results
28th Feb 20207:00 amRNSTotal Voting Rights
11th Feb 20202:36 pmRNSTrading Update
3rd Feb 20207:00 amRNSBlock listing Six Monthly Return
30th Jan 20207:00 amRNSTreasury Shares,Share Capital,Total Voting Rights
27th Dec 20199:19 amRNSIncrease in shareholder loan
20th Dec 201911:36 amRNSUpdate re Board of Directors
12th Dec 201911:29 amRNSDisposal of Starry Shares
22nd Nov 201911:31 amRNSNew shareholder loan
31st Oct 20199:57 amRNSRetirement of an Executive Director
31st Oct 20197:12 amRNSTotal Voting Rights
30th Sep 20197:00 amRNSTotal Voting Rights
25th Sep 201910:36 amRNSDisposal of Starry Shares
18th Sep 201912:10 pmRNSDisposal of Starry Shares
11th Sep 201911:37 amRNSLansen's fifth share reduction plan of Starry
10th Sep 20193:10 pmRNSDisposal of Starry Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.